KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Investments (2016 - 2026)

Alnylam Pharmaceuticals filings provide 18 years of Long-Term Investments readings, the most recent being $22.2 million for Q1 2026.

  • On a quarterly basis, Long-Term Investments fell 67.68% to $22.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $22.2 million, a 67.68% decrease, with the full-year FY2025 number at $22.2 million, down 67.68% from a year prior.
  • Long-Term Investments hit $22.2 million in Q1 2026 for Alnylam Pharmaceuticals, roughly flat from $22.2 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $68.6 million in Q4 2024 to a low of $22.2 million in Q4 2025.
  • Median Long-Term Investments over the past 5 years was $49.4 million (2022), compared with a mean of $50.3 million.
  • Biggest five-year swings in Long-Term Investments: surged 38.88% in 2024 and later tumbled 67.68% in 2025.
  • Alnylam Pharmaceuticals' Long-Term Investments stood at $49.4 million in 2022, then rose by 0.0% to $49.4 million in 2023, then surged by 38.88% to $68.6 million in 2024, then tumbled by 67.68% to $22.2 million in 2025, then changed by 0.0% to $22.2 million in 2026.
  • The last three reported values for Long-Term Investments were $22.2 million (Q1 2026), $22.2 million (Q4 2025), and $51.3 million (Q3 2025) per Business Quant data.